These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 29336874)
1. Regioselectivity of thiouracil alkylation: Application to optimization of Darapladib synthesis. Guibbal F; Bénard S; Patché J; Meneyrol V; Couprie J; Yong-Sang J; Meilhac O; Jestin E Bioorg Med Chem Lett; 2018 Feb; 28(4):787-792. PubMed ID: 29336874 [TBL] [Abstract][Full Text] [Related]
2. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis. Zhang J; Xu DL; Liu XB; Bi SJ; Zhao T; Sui SJ; Ji XP; Lu QH Yonsei Med J; 2016 Mar; 57(2):321-7. PubMed ID: 26847282 [TBL] [Abstract][Full Text] [Related]
3. Active site competition is the mechanism for the inhibition of lipoprotein-associated phospholipase A Zhuo S; Yuan C Sci Rep; 2020 Oct; 10(1):17232. PubMed ID: 33057060 [TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of imidazole and triazole derivatives as Lp-PLA₂ inhibitors and the unexpected discovery of highly potent quaternary ammonium salts. Wang K; Xu W; Liu Y; Zhang W; Wang W; Shen J; Wang Y Bioorg Med Chem Lett; 2013 Mar; 23(5):1187-92. PubMed ID: 23385210 [TBL] [Abstract][Full Text] [Related]
5. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A; J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114 [TBL] [Abstract][Full Text] [Related]
6. Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation. Lv SL; Zeng ZF; Gan WQ; Wang WQ; Li TG; Hou YF; Yan Z; Zhang RX; Yang M Acta Pharmacol Sin; 2021 Dec; 42(12):2016-2032. PubMed ID: 34226664 [TBL] [Abstract][Full Text] [Related]
7. Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors. Liu Q; Chen X; Chen W; Yuan X; Su H; Shen J; Xu Y J Med Chem; 2016 May; 59(10):5115-20. PubMed ID: 27078579 [TBL] [Abstract][Full Text] [Related]
8. Chronic inhibition of lipoprotein-associated phospholipase A Prasad M; Lennon R; Barsness GW; Prasad A; Gulati R; Lerman LO; Lerman A Int J Cardiol; 2018 Feb; 253():7-13. PubMed ID: 29306475 [TBL] [Abstract][Full Text] [Related]
9. Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2. Fenning RS; Burgert ME; Hamamdzic D; Peyster EG; Mohler ER; Kangovi S; Jucker BM; Lenhard SC; Macphee CH; Wilensky RL J Am Heart Assoc; 2015 Feb; 4(2):. PubMed ID: 25672369 [TBL] [Abstract][Full Text] [Related]
10. Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors. Wang K; Xu W; Zhang W; Mo M; Wang Y; Shen J Bioorg Med Chem Lett; 2013 May; 23(10):2897-901. PubMed ID: 23575276 [TBL] [Abstract][Full Text] [Related]
11. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe. Daida H; Iwase T; Yagi S; Ando H; Nakajima H Circ J; 2013; 77(6):1518-25. PubMed ID: 23439604 [TBL] [Abstract][Full Text] [Related]